Does the media prefer GMED or IDXX?

In the previous week, IDEXX Laboratories had 1 more articles in the media than Globus Medical. MarketBeat recorded 6 mentions for IDEXX Laboratories and 5 mentions for Globus Medical. IDEXX Laboratories' average media sentiment score of 0.80 beat Globus Medical's score of 0.43 indicating that IDEXX Laboratories is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Globus Medical 1 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral IDEXX Laboratories 3 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer BDX or GMED?

In the previous week, Becton, Dickinson and Company had 20 more articles in the media than Globus Medical. MarketBeat recorded 25 mentions for Becton, Dickinson and Company and 5 mentions for Globus Medical. Becton, Dickinson and Company's average media sentiment score of 1.14 beat Globus Medical's score of 0.43 indicating that Becton, Dickinson and Company is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Becton, Dickinson and Company 17 Very Positive mention(s) 2 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Globus Medical 1 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has preferable valuation and earnings, GMED or DXCM?

DexCom has higher revenue and earnings than Globus Medical. Globus Medical is trading at a lower price-to-earnings ratio than DexCom, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Globus Medical $3.10B 3.50 $537.87M $4.30 18.61 DexCom $4.66B 6.01 $836.30M $2.34 31.02

Is GMED or DXCM more profitable?

DexCom has a net margin of 19.31% compared to Globus Medical's net margin of 18.92%. DexCom's return on equity of 33.33% beat Globus Medical's return on equity. Company Net Margins Return on Equity Return on Assets Globus Medical 18.92% 13.46% 11.65% DexCom 19.31% 33.33% 13.19%

Does the media favor GMED or DXCM?

In the previous week, DexCom had 15 more articles in the media than Globus Medical. MarketBeat recorded 20 mentions for DexCom and 5 mentions for Globus Medical. DexCom's average media sentiment score of 1.49 beat Globus Medical's score of 0.43 indicating that DexCom is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Globus Medical 1 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral DexCom 16 Very Positive mention(s) 3 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has preferable earnings and valuation, RMD or GMED?

ResMed has higher revenue and earnings than Globus Medical. Globus Medical is trading at a lower price-to-earnings ratio than ResMed, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio ResMed $5.15B 5.47 $1.40B $10.37 18.72 Globus Medical $3.10B 3.50 $537.87M $4.30 18.61

Is RMD or GMED more profitable?

ResMed has a net margin of 27.44% compared to Globus Medical's net margin of 18.92%. ResMed's return on equity of 25.35% beat Globus Medical's return on equity. Company Net Margins Return on Equity Return on Assets ResMed 27.44% 25.35% 18.69% Globus Medical 18.92% 13.46% 11.65%

Does the media refer more to RMD or GMED?

In the previous week, ResMed had 15 more articles in the media than Globus Medical. MarketBeat recorded 20 mentions for ResMed and 5 mentions for Globus Medical. ResMed's average media sentiment score of 1.24 beat Globus Medical's score of 0.43 indicating that ResMed is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment ResMed 13 Very Positive mention(s) 2 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Globus Medical 1 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has stronger earnings & valuation, STE or GMED?

STERIS has higher revenue and earnings than Globus Medical. Globus Medical is trading at a lower price-to-earnings ratio than STERIS, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio STERIS $5.94B 3.49 $782.30M $7.93 26.74 Globus Medical $3.10B 3.50 $537.87M $4.30 18.61

Is STE or GMED more profitable?

Globus Medical has a net margin of 18.92% compared to STERIS's net margin of 13.18%. STERIS's return on equity of 14.15% beat Globus Medical's return on equity. Company Net Margins Return on Equity Return on Assets STERIS 13.18% 14.15% 9.52% Globus Medical 18.92% 13.46% 11.65%

Does the media favor STE or GMED?

In the previous week, STERIS had 2 more articles in the media than Globus Medical. MarketBeat recorded 7 mentions for STERIS and 5 mentions for Globus Medical. STERIS's average media sentiment score of 1.18 beat Globus Medical's score of 0.43 indicating that STERIS is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment STERIS 6 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Globus Medical 1 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Globus Medical (GMED) Competitors

$80.03 +2.08 (+2.67%)

Closing price 06/4/2026 03:59 PM Eastern

Extended Trading

$80.75 +0.72 (+0.90%)

As of 06/4/2026 07:56 PM Eastern

Compare

GMED vs. IDXX, BDX, DXCM, RMD, and STE

Should you buy Globus Medical stock or one of its competitors? MarketBeat compares Globus Medical with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Globus Medical include IDEXX Laboratories (IDXX), Becton, Dickinson and Company (BDX), DexCom (DXCM), ResMed (RMD), and STERIS (STE). These companies are all part of the "health care equipment" industry.

How does Globus Medical compare to IDEXX Laboratories?

Globus Medical (NYSE:GMED) and IDEXX Laboratories (NASDAQ:IDXX) are both large-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their analyst recommendations, profitability, risk, institutional ownership, valuation, dividends, media sentiment and earnings.

Globus Medical currently has a consensus price target of $106.36, suggesting a potential upside of 32.91%. IDEXX Laboratories has a consensus price target of $751.00, suggesting a potential upside of 32.98%. Given IDEXX Laboratories' higher probable upside, analysts plainly believe IDEXX Laboratories is more favorable than Globus Medical.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Globus Medical	0 Sell rating(s)	4 Hold rating(s)	9 Buy rating(s)	2 Strong Buy rating(s)	2.87
IDEXX Laboratories	0 Sell rating(s)	4 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.64

IDEXX Laboratories has a net margin of 24.63% compared to Globus Medical's net margin of 18.92%. IDEXX Laboratories' return on equity of 70.87% beat Globus Medical's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Globus Medical	18.92%	13.46%	11.65%
IDEXX Laboratories	24.63%	70.87%	32.56%

Globus Medical has a beta of 0.95, meaning that its share price is 5% less volatile than the broader market. Comparatively, IDEXX Laboratories has a beta of 1.55, meaning that its share price is 55% more volatile than the broader market.

95.2% of Globus Medical shares are held by institutional investors. Comparatively, 87.8% of IDEXX Laboratories shares are held by institutional investors. 18.4% of Globus Medical shares are held by insiders. Comparatively, 0.8% of IDEXX Laboratories shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

IDEXX Laboratories has higher revenue and earnings than Globus Medical. Globus Medical is trading at a lower price-to-earnings ratio than IDEXX Laboratories, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Globus Medical	$3.10B	3.50	$537.87M	$4.30	18.61
IDEXX Laboratories	$4.30B	10.35	$1.06B	$13.58	41.59

In the previous week, IDEXX Laboratories had 1 more articles in the media than Globus Medical. MarketBeat recorded 6 mentions for IDEXX Laboratories and 5 mentions for Globus Medical. IDEXX Laboratories' average media sentiment score of 0.80 beat Globus Medical's score of 0.43 indicating that IDEXX Laboratories is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Globus Medical	1 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
IDEXX Laboratories	3 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

IDEXX Laboratories beats Globus Medical on 12 of the 17 factors compared between the two stocks.

How does Globus Medical compare to Becton, Dickinson and Company?

Becton, Dickinson and Company (NYSE:BDX) and Globus Medical (NYSE:GMED) are both large-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, media sentiment, risk, institutional ownership, profitability, analyst recommendations, valuation and dividends.

87.0% of Becton, Dickinson and Company shares are owned by institutional investors. Comparatively, 95.2% of Globus Medical shares are owned by institutional investors. 0.4% of Becton, Dickinson and Company shares are owned by insiders. Comparatively, 18.4% of Globus Medical shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Becton, Dickinson and Company has higher revenue and earnings than Globus Medical. Globus Medical is trading at a lower price-to-earnings ratio than Becton, Dickinson and Company, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Becton, Dickinson and Company	$21.84B	1.89	$1.68B	$3.95	37.84
Globus Medical	$3.10B	3.50	$537.87M	$4.30	18.61

In the previous week, Becton, Dickinson and Company had 20 more articles in the media than Globus Medical. MarketBeat recorded 25 mentions for Becton, Dickinson and Company and 5 mentions for Globus Medical. Becton, Dickinson and Company's average media sentiment score of 1.14 beat Globus Medical's score of 0.43 indicating that Becton, Dickinson and Company is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Becton, Dickinson and Company	17 Very Positive mention(s)	2 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Globus Medical	1 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Becton, Dickinson and Company has a beta of 0.22, suggesting that its stock price is 78% less volatile than the broader market. Comparatively, Globus Medical has a beta of 0.95, suggesting that its stock price is 5% less volatile than the broader market.

Becton, Dickinson and Company currently has a consensus price target of $183.64, suggesting a potential upside of 22.87%. Globus Medical has a consensus price target of $106.36, suggesting a potential upside of 32.91%. Given Globus Medical's stronger consensus rating and higher probable upside, analysts plainly believe Globus Medical is more favorable than Becton, Dickinson and Company.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Becton, Dickinson and Company	1 Sell rating(s)	8 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.38
Globus Medical	0 Sell rating(s)	4 Hold rating(s)	9 Buy rating(s)	2 Strong Buy rating(s)	2.87

Globus Medical has a net margin of 18.92% compared to Becton, Dickinson and Company's net margin of 5.33%. Becton, Dickinson and Company's return on equity of 15.37% beat Globus Medical's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Becton, Dickinson and Company	5.33%	15.37%	7.11%
Globus Medical	18.92%	13.46%	11.65%

Summary

Globus Medical beats Becton, Dickinson and Company on 11 of the 17 factors compared between the two stocks.

How does Globus Medical compare to DexCom?

Globus Medical (NYSE:GMED) and DexCom (NASDAQ:DXCM) are both large-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their media sentiment, risk, analyst recommendations, dividends, earnings, profitability, valuation and institutional ownership.

95.2% of Globus Medical shares are owned by institutional investors. Comparatively, 97.8% of DexCom shares are owned by institutional investors. 18.4% of Globus Medical shares are owned by company insiders. Comparatively, 0.3% of DexCom shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Globus Medical currently has a consensus target price of $106.36, indicating a potential upside of 32.91%. DexCom has a consensus target price of $82.42, indicating a potential upside of 13.54%. Given Globus Medical's higher possible upside, equities research analysts clearly believe Globus Medical is more favorable than DexCom.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Globus Medical	0 Sell rating(s)	4 Hold rating(s)	9 Buy rating(s)	2 Strong Buy rating(s)	2.87
DexCom	1 Sell rating(s)	3 Hold rating(s)	19 Buy rating(s)	3 Strong Buy rating(s)	2.92

DexCom has a net margin of 19.31% compared to Globus Medical's net margin of 18.92%. DexCom's return on equity of 33.33% beat Globus Medical's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Globus Medical	18.92%	13.46%	11.65%
DexCom	19.31%	33.33%	13.19%

DexCom has higher revenue and earnings than Globus Medical. Globus Medical is trading at a lower price-to-earnings ratio than DexCom, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Globus Medical	$3.10B	3.50	$537.87M	$4.30	18.61
DexCom	$4.66B	6.01	$836.30M	$2.34	31.02

In the previous week, DexCom had 15 more articles in the media than Globus Medical. MarketBeat recorded 20 mentions for DexCom and 5 mentions for Globus Medical. DexCom's average media sentiment score of 1.49 beat Globus Medical's score of 0.43 indicating that DexCom is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Globus Medical	1 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
DexCom	16 Very Positive mention(s)	3 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Globus Medical has a beta of 0.95, suggesting that its share price is 5% less volatile than the broader market. Comparatively, DexCom has a beta of 1.45, suggesting that its share price is 45% more volatile than the broader market.

Summary

DexCom beats Globus Medical on 14 of the 17 factors compared between the two stocks.

How does Globus Medical compare to ResMed?

ResMed (NYSE:RMD) and Globus Medical (NYSE:GMED) are both large-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their dividends, earnings, institutional ownership, risk, media sentiment, valuation, profitability and analyst recommendations.

ResMed has a net margin of 27.44% compared to Globus Medical's net margin of 18.92%. ResMed's return on equity of 25.35% beat Globus Medical's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
ResMed	27.44%	25.35%	18.69%
Globus Medical	18.92%	13.46%	11.65%

ResMed has a beta of 0.8, indicating that its stock price is 20% less volatile than the broader market. Comparatively, Globus Medical has a beta of 0.95, indicating that its stock price is 5% less volatile than the broader market.

ResMed has higher revenue and earnings than Globus Medical. Globus Medical is trading at a lower price-to-earnings ratio than ResMed, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ResMed	$5.15B	5.47	$1.40B	$10.37	18.72
Globus Medical	$3.10B	3.50	$537.87M	$4.30	18.61

55.0% of ResMed shares are owned by institutional investors. Comparatively, 95.2% of Globus Medical shares are owned by institutional investors. 0.7% of ResMed shares are owned by company insiders. Comparatively, 18.4% of Globus Medical shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

ResMed currently has a consensus price target of $286.18, suggesting a potential upside of 47.42%. Globus Medical has a consensus price target of $106.36, suggesting a potential upside of 32.91%. Given ResMed's higher probable upside, equities analysts clearly believe ResMed is more favorable than Globus Medical.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ResMed	0 Sell rating(s)	5 Hold rating(s)	9 Buy rating(s)	1 Strong Buy rating(s)	2.73
Globus Medical	0 Sell rating(s)	4 Hold rating(s)	9 Buy rating(s)	2 Strong Buy rating(s)	2.87

In the previous week, ResMed had 15 more articles in the media than Globus Medical. MarketBeat recorded 20 mentions for ResMed and 5 mentions for Globus Medical. ResMed's average media sentiment score of 1.24 beat Globus Medical's score of 0.43 indicating that ResMed is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
ResMed	13 Very Positive mention(s)	2 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Globus Medical	1 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

ResMed beats Globus Medical on 11 of the 16 factors compared between the two stocks.

How does Globus Medical compare to STERIS?

STERIS (NYSE:STE) and Globus Medical (NYSE:GMED) are both large-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their dividends, earnings, profitability, institutional ownership, risk, valuation, media sentiment and analyst recommendations.

Globus Medical has a net margin of 18.92% compared to STERIS's net margin of 13.18%. STERIS's return on equity of 14.15% beat Globus Medical's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
STERIS	13.18%	14.15%	9.52%
Globus Medical	18.92%	13.46%	11.65%

94.7% of STERIS shares are held by institutional investors. Comparatively, 95.2% of Globus Medical shares are held by institutional investors. 1.1% of STERIS shares are held by insiders. Comparatively, 18.4% of Globus Medical shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

STERIS has a beta of 0.93, meaning that its stock price is 7% less volatile than the broader market. Comparatively, Globus Medical has a beta of 0.95, meaning that its stock price is 5% less volatile than the broader market.

STERIS presently has a consensus price target of $278.00, suggesting a potential upside of 31.08%. Globus Medical has a consensus price target of $106.36, suggesting a potential upside of 32.91%. Given Globus Medical's stronger consensus rating and higher possible upside, analysts clearly believe Globus Medical is more favorable than STERIS.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
STERIS	0 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.75
Globus Medical	0 Sell rating(s)	4 Hold rating(s)	9 Buy rating(s)	2 Strong Buy rating(s)	2.87

STERIS has higher revenue and earnings than Globus Medical. Globus Medical is trading at a lower price-to-earnings ratio than STERIS, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
STERIS	$5.94B	3.49	$782.30M	$7.93	26.74
Globus Medical	$3.10B	3.50	$537.87M	$4.30	18.61

In the previous week, STERIS had 2 more articles in the media than Globus Medical. MarketBeat recorded 7 mentions for STERIS and 5 mentions for Globus Medical. STERIS's average media sentiment score of 1.18 beat Globus Medical's score of 0.43 indicating that STERIS is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
STERIS	6 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Globus Medical	1 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Globus Medical beats STERIS on 10 of the 17 factors compared between the two stocks.

Get Globus Medical News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding GMED and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

GMED vs. The Competition

Export

Metric	Globus Medical	MED INSTRUMENTS Industry	Medical Sector	NYSE Exchange
Market Cap	$10.58B	$7.25B	$6.30B	$23.09B
Dividend Yield	N/A	1.23%	2.69%	4.09%
P/E Ratio	18.61	46.43	23.78	31.05
Price / Sales	3.50	47.34	532.69	23.99
Price / Cash	12.41	24.16	41.39	24.44
Price / Book	2.36	7.30	10.04	4.72
Net Income	$537.87M	$159.22M	$3.56B	$1.07B
7 Day Performance	-2.40%	1.02%	-0.99%	-0.06%
1 Month Performance	-11.05%	6.48%	2.25%	0.97%
1 Year Performance	34.61%	3.53%	29.11%	25.95%

Globus Medical Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
GMED Globus Medical	4.1205 of 5 stars	$80.03 +2.7%	$106.36 +32.9%	+34.1%	$10.58B	$3.10B	18.61	6,000
IDXX IDEXX Laboratories	4.179 of 5 stars	$566.79 +0.6%	$751.00 +32.5%	+7.6%	$44.45B	$4.30B	41.74	11,000
BDX Becton, Dickinson and Company	4.7559 of 5 stars	$145.35 -1.2%	$183.64 +26.3%	-12.5%	$40.54B	$21.84B	36.80	72,000	Positive News Insider Trade Gap Up
DXCM DexCom	4.5353 of 5 stars	$74.87 +1.5%	$82.42 +10.1%	-15.2%	$28.45B	$4.66B	32.00	11,000	Positive News
RMD ResMed	4.8871 of 5 stars	$186.58 -2.1%	$286.18 +53.4%	-22.3%	$27.64B	$5.15B	17.99	10,600	Positive News Gap Up

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NYSE:GMED) was last updated on 6/5/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Globus Medical (GMED) Competitors

GMED vs. IDXX, BDX, DXCM, RMD, and STE

How does Globus Medical compare to IDEXX Laboratories?

Summary

How does Globus Medical compare to Becton, Dickinson and Company?

Summary

How does Globus Medical compare to DexCom?

Summary

How does Globus Medical compare to ResMed?

Summary

How does Globus Medical compare to STERIS?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

GMED vs. The Competition

Globus Medical Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Globus Medical (GMED) Competitors

GMED vs. IDXX, BDX, DXCM, RMD, and STE

How does Globus Medical compare to IDEXX Laboratories?

Do analysts rate GMED or IDXX?

Is GMED or IDXX more profitable?

Which has more volatility & risk, GMED or IDXX?

Do insiders & institutionals have more ownership in GMED or IDXX?

Which has better earnings & valuation, GMED or IDXX?

Does the media prefer GMED or IDXX?

Summary

How does Globus Medical compare to Becton, Dickinson and Company?

Do institutionals & insiders have more ownership in BDX or GMED?

Which has stronger earnings & valuation, BDX or GMED?

Does the media prefer BDX or GMED?

Which has more volatility and risk, BDX or GMED?

Do analysts recommend BDX or GMED?

Is BDX or GMED more profitable?

Summary

How does Globus Medical compare to DexCom?

Do insiders and institutionals believe in GMED or DXCM?

Do analysts rate GMED or DXCM?

Is GMED or DXCM more profitable?

Which has preferable valuation and earnings, GMED or DXCM?

Does the media favor GMED or DXCM?

Which has more risk & volatility, GMED or DXCM?

Summary

How does Globus Medical compare to ResMed?

Is RMD or GMED more profitable?

Which has more risk and volatility, RMD or GMED?

Which has preferable earnings and valuation, RMD or GMED?

Do insiders and institutionals hold more shares of RMD or GMED?

Do analysts prefer RMD or GMED?

Does the media refer more to RMD or GMED?

Summary

How does Globus Medical compare to STERIS?

Is STE or GMED more profitable?

Do insiders and institutionals have more ownership in STE or GMED?

Which has more volatility & risk, STE or GMED?

Do analysts prefer STE or GMED?

Which has stronger earnings & valuation, STE or GMED?

Does the media favor STE or GMED?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

GMED vs. The Competition

Globus Medical Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools